QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price ta...

Core News & Articles

https://www.axios.com/pro/biotech-deals/2025/10/10/cero-therapeutics-ceo-open-takeover-offers

Core News & Articles

https://register.epo.org/application?number=EP22758100

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price ta...

Core News & Articles

Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional resul...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price ta...

Core News & Articles

Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering t...

Core News & Articles

CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative cellular immunotherapy ...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price ta...

Core News & Articles

CERo Therapeutics Hldgs (NASDAQ:CERO) reported quarterly losses of $(61.71) per share which missed the analyst consensus estima...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price ta...

Core News & Articles

Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update o...

Core News & Articles

-SEC Filing

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price ta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION